Medical Net,Inc.

Medical Net <3645> is surging. The company announced on the 3rd that it received approval from the Tokyo Stock Exchange to change its market classification to the Standard Market, and will transfer from the Growth Market to the Standard Market effective September 10. Additionally, it received notification that the supervision designation (under review) that had been designated by the TSE effective June 1 will be lifted effective September 4.

In individual announcements released on the 26th, ABEJA resolved to establish a wholly-owned subsidiary in Singapore. Globing plans a significant profit increase and higher dividend for the fiscal year ending May 2027 (IFRS). Susmed's exclusive sales contract with Shionogi for its insomnia disorder app has ended. Nexera received a milestone payment of approximately 1.591 billion yen related to its partner Neurocrine's Phase 2 trial for cognitive impairment in Alzheimer's disease. Kasumigaseki Capital sold a property held for sale (Miami development land) for its first U.S. project, and Yamaha announced the partial sale of its shares in Yamaha Motor. Matsui Securities set its interim dividend for the fiscal year ending March 2027 at 28 yen (compared to 25 yen in the same period last year), and Medical Net resolved the material weakness in internal control over financial reporting that had been disclosed.